secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004554
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health: initial REVEAL-1 data show weight maintenance post-GLP-1 discontinuation; REMAIN-1 enrollment strong
--------------------------------------------------------------------------------

- First REVEAL-1 patient achieved 15% total body weight loss on tirzepatide, then maintained weight 1 month after Revita post-discontinuation.
- Prior studies show average 3% weight regain within 4 weeks of GLP-1 discontinuation, highlighting Revita potential.
- Over 100 patients enrolled across 8 sites in REMAIN-1 study in less than 4 months; high demand.
- REVEAL-1 cohort data presentation delayed to Q1 2025 due to holiday scheduling; mid-point analysis expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025004554/0000950170-25-004554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025004554/guts-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer